Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
88.79+0.07 (+0.08%)
At close: 04:00PM EDT
88.79 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

    - VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone - These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma

  • GlobeNewswire

    Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments

    - Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial Officer, will retire and become a senior advisor to Ascendis Pharma - Endocrinology commercial team will continue to focus on building U.S. market leadership for SKYTROFA® (lonapegsomatropin-tcgd) and preparing for other anticipated TransCon™

  • Investor's Business Daily

    Ascendis Reverses Its Losses After A Key Drug Misses Sales Forecasts

    Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.

Advertisement
Advertisement